Also known as: radioligand therapies
Novartis finalized a seventh new US facility as part of a $23 billion expansion. The new API site in Morrisville, North Carolina, supports end-to-end US manufacturing across multiple therapy platforms.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
Bayer achieved its upgraded 2025 financial targets with group sales reaching 45.6 billion euros and projects solid 2026 performance. The company's pharmaceutical business shows rejuvenation with launch medicines becoming growth drivers, while Crop Science progresses in profitability improvement. Bayer continues strategic diversification in oncology and addresses litigation challenges while implementing cost-saving measures.
Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on March 27, 2026, featuring discussions on epigenetic therapies, microbiome-driven immunity, and cellular pathway reprogramming. The event continues collaboration between Dana-Farber and France's Gustave Roussy cancer center with support from L'Institut Servier and Medscape Medical Affairs.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
Pluvicto (lutetium-177 vipivotide tetraxetan) received MHRA authorization for earlier use in metastatic castration-resistant prostate cancer, while pooled trial data demonstrates improved progression-free survival without increased toxicity.
Novartis announced plans to establish a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion US expansion. The facility is expected to be operational in 2028.
Novartis announced positive Phase III ALIGN results for Vanrafia in IgA nephropathy and plans to build a new radioligand therapy manufacturing site in Denton, Texas, operational by 2028.
Former Novartis executive John Tsai has been appointed global head of R&D at Daiichi Sankyo, replacing Ken Takeshita effective April 1. Tsai brings over 25 years of leadership experience in drug development.
President Trump announced that Novartis CEO met with him at the White House and said the Swiss drugmaker is building 11 U.S. plants following tariff policies. Novartis previously committed $23 billion to expand U.S. facilities.
